by SignalFactory · November 1, 2021 | 10:58:13 UTC
Pfizer (NYSE: PFE) to beat expectations when it reports third-quarter 2021 results on Nov 2, before the market open. In the last reported quarter, the company beat earnings expectations by 10.31%.
Factors to Note: A key contributor to Pfizer’s sales in the third quarter is likely to have been its and partner BioNTech’s BNTX COVID-19 vaccine, Comirnaty. Sales are expected to be higher than second-quarter sales of $7.8 billion.
Higher sales of Pfizer’s key brands, Eliquis [alliance revenues from Bristol Myers BMY], Xtandi and Inlyta, and significant contribution from newer drug Vyndaqel/Vyndamax and higher biosimilar revenues are likely to have contributed to sales growth in the third quarter of 2021.
Sales of Prevnar 13/Prevenar 13 vaccine, which were hurt significantly by the pandemic in the previous quarters, improved in the United States in the second quarter. We expect the positive trend to have continued in the third quarter.
Ibrance sales are likely to have risen outside U.S. markets, which might have made up for lower sales in the United States.
The Zacks Consensus Estimate for oncology and vaccine products is $3.19 billion and $14.51 billion, respectively.
However, sales of some key drugs like Chantix in the United States and Enbrel in international markets are likely to have declined in the third quarter, continuing the trend of the past few quarters. While Chantix sales are expected to have been hurt by the loss of exclusivity, sales of Enbrel in key European markets and Japan are likely to have been hurt by biosimilar competition.
R&D costs are expected to have been higher in the third quarter due to incremental spending on COVID-19 vaccines and antiviral medicines as well as other mRNA-based programs.
Key Recent Development: Last month, the FDA granted emergency use authorization (EUA) to a booster or “third” dose of Comirnaty for individuals 65 years and older and those in high-risk groups.
The high-risk groups include individuals aged 16 to 64, at a high risk of severe COVID-19, and those whose occupation exposes them to the virus and puts them at a high risk of COVID-related complications, including severe COVID-19, like healthcare workers, teachers, and others. However, in line with the recommendation of the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC), the FDA did not approve the booster dose for the entire population for which Pfizer/BioNTech was seeking approval. Pfizer/BioNTech had filed its supplemental biologics license application (sBLA), seeking approval for the booster dose of Comirnaty, in people 16 years of age and older, in August.
Pfizer’s pivotal phase II/III study showed that its COVID-19 vaccine was safe, well-tolerated, and initiated robust neutralizing antibody responses in children 5 to 11 years of age. Data from the study cohort showed that one month of immunization with two doses of Comirnaty resulted in SARS-CoV-2–neutralizing antibody geometric mean titer levels that were non-inferior to the level achieved in individuals aged 16 to 25 years of age in the previously completed clinical study. This week, the VRBPAC voted in favor (17 to 0, with one abstention) of the FDA granting EUA to Comirnaty for kids of this age group. The FDA authorizes Pfizer’s COVID-19 vaccine for children ages 5 to 11.
Earnings ESP: Pfizer’s Earnings ESP is +2.25% as the Most Accurate Estimate of $1.11 per share is pegged higher than the Zacks Consensus Estimate of $1.08 per share.
Pfizer Long (Buy) Enter At: 44.09 T.P_1: 44.85 T.P_2: 45.84 T.P_3: 46.52 T.P_4: 47.48 S.L: 41.70
All information on this website is of a general nature. The information is not adapted to conditions that are specific to your person or entity. The information provided can not be considered as personal, professional or legal advice or investment advice to the user.
This website and all information is intended for educational purposes only and does not give financial advice. Signal Factory is not a service to provide legal and financial advice; any information provided here is only the personal opinion of the author (not advice or financial advice in any sense, and in the sense of any act, ordinance or law of any country) and must not be used for financial activities. Signal Factory does not offer, operate or provide financial, brokerage, commercial or investment services and is not a financial advisor. Rather, Signal Factory is an educational site and a platform for exchanging Forex information. Whenever information is disclosed, whether express or implied, about profit or revenue, it is not a guarantee. No method or trading system ensures that it will generate a profit, so always remember that trade can lead to a loss. Trading responsibility, whether resulting in profits or losses, is yours and you must agree not to hold Signal Factory or other information providers that are responsible in any way whatsoever. The use of the system means that the user accepts Disclaimer and Terms of Use.
Signal Factory is not represented as a registered investment consultant or brokerage dealer nor offers to buy or sell any of the financial instruments mentioned in the service offered.
While Signal Factory believes that the content provided is accurate, there are no explicit or implied warranties of accuracy. The information provided is believed to be reliable; Signal Factory does not guarantee the accuracy or completeness of the information provided. Third parties refer to Signal Factory to provide technology and information if a third party fails, and then there is a risk that the information may be delayed or not delivered at all.
All information and comments contained on this website, including but not limited to, opinions, analyzes, news, prices, research, and general, do not constitute investment advice or an invitation to buy or sell any type of instrument. Signal Factory assumes no responsibility for any loss or damage that may result, directly or indirectly, from the use or dependence on such information.
All information contained on this web site is a personal opinion or belief of the author. None of these data is a recommendation or financial advice in any sense, also within the meaning of any commercial act or law. Writers, publishers and affiliates of Signal Factory are not responsible for your trading in any way.
The information and opinions contained in the site are provided for information only and for educational reasons, should never be considered as direct or indirect advice to open a trading account and / or invest money in Forex trading with any Forex company . Signal Factory assumes no responsibility for any decisions taken by the user to create a merchant account with any of the brokers listed on this website. Anyone who decides to set up a merchant account or use the services, free of charge or paid, to any of the Forex companies mentioned on this website, bears full responsibility for their actions.
Any institution that offers a service and is listed on this website, including forex brokers, financial companies and other institutions, is present only for informational purposes. All ratings, ratings, banners, reviews, or other information found for any of the above-mentioned institutions are provided in a strictly objective manner and according to the best possible reflection of the materials on the official website of the company.
Forex trading is potentially high risk and may not be suitable for all investors. The high level of leverage can work both for and against merchants. Before each Forex investment, you should carefully consider your goals, past experience and risk level. The opinions and data contained on this site should not be considered as suggestions or advice for the sale or purchase of currency or other instruments. Past results do not show or guarantee future results.
Neither Signal Factory nor its affiliates ensure the accuracy of the content provided on this Site. You explicitly agree that viewing, visiting or using this website is at your own risk.
